Oncopeptides Partners with Veeva to Drive More Effective Engagement Ahead of First Commercial Launch
Oncopeptides Partners with Veeva to Drive More Effective Engagement Ahead of First Commercial Launch Veeva Link provides biotech with valuable market insights about top scientific and clinical leaders News provided by Share this article PLEASANTON, Calif., May 17, 2021 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced a strategic partnership with Oncopeptides to support the launch of the global biotech's first commercial product. Using Veeva Link for real-time customer intelligence, Oncopeptides recently launched PEPAXTO® (melphalan flufenamide), the first anticancer peptide-dru...